Clinical and Basic Research of ETV Plus GM-CSF in Chronic Hepatitis B Patients
Status:
Unknown status
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
Previous studies indicated that Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)
could improve survival rate in patients with acute liver failure and obtain higher HBsAg
seroconversion rate when in combination with peg-interferon for chronic hepatitis B (CHB)
patients. In this study, investigators will study the clinical effect of entecavir (ETV) plus
GM-CSF in patients with CHB compared to ETV monotherapy.